Clinical Trials
8 trialsNCT05687721 2025-06-15
Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer
VA Office of Research and Development
Phase 1/2 Withdrawn
NCT04685915 2025-05-22
Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT06218667 2024-10-31
A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Withdrawn
NCT05295589 2023-09-26
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT03803761 2023-09-25
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT05010096 2022-05-27
BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT04233697 2020-08-13
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
Columbia University
Phase 1 Withdrawn
NCT03377101 2018-08-14
Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn